1976 related articles for article (PubMed ID: 16230722)
1. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
[TBL] [Abstract][Full Text] [Related]
2. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
[TBL] [Abstract][Full Text] [Related]
3. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
Buse JB; Bergenstal RM; Glass LC; Heilmann CR; Lewis MS; Kwan AY; Hoogwerf BJ; Rosenstock J
Ann Intern Med; 2011 Jan; 154(2):103-12. PubMed ID: 21138825
[TBL] [Abstract][Full Text] [Related]
4. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
Zinman B; Hoogwerf BJ; Durán García S; Milton DR; Giaconia JM; Kim DD; Trautmann ME; Brodows RG
Ann Intern Med; 2007 Apr; 146(7):477-85. PubMed ID: 17404349
[TBL] [Abstract][Full Text] [Related]
5. Summaries for patients. Exenatide or insulin glargine for suboptimally controlled diabetes?
Ann Intern Med; 2005 Oct; 143(8):I30. PubMed ID: 16230718
[No Abstract] [Full Text] [Related]
6. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
Inagaki N; Atsumi Y; Oura T; Saito H; Imaoka T
Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
[TBL] [Abstract][Full Text] [Related]
8. Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA.
Matyjaszek-Matuszek B; Lenart-Lipińska M; Rogalska D; Nowakowski A;
Endokrynol Pol; 2013; 64(5):375-82. PubMed ID: 24186595
[TBL] [Abstract][Full Text] [Related]
9. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
Meneghini LF; Traylor L; Schwartz SL
Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
Diamant M; Nauck MA; Shaginian R; Malone JK; Cleall S; Reaney M; de Vries D; Hoogwerf BJ; MacConell L; Wolffenbuttel BH;
Diabetes Care; 2014 Oct; 37(10):2763-73. PubMed ID: 25011946
[TBL] [Abstract][Full Text] [Related]
11. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.
Bunck MC; Diamant M; Cornér A; Eliasson B; Malloy JL; Shaginian RM; Deng W; Kendall DM; Taskinen MR; Smith U; Yki-Järvinen H; Heine RJ
Diabetes Care; 2009 May; 32(5):762-8. PubMed ID: 19196887
[TBL] [Abstract][Full Text] [Related]
12. The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial.
de Lapertosa SB; Frechtel G; Hardy E; Sauque-Reyna L
Diabetes Res Clin Pract; 2016 Dec; 122():38-45. PubMed ID: 27776251
[TBL] [Abstract][Full Text] [Related]
13. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of exenatide in Asian Indians in a clinical care setting.
Sudhakaran C; Fathima M; Anjana RM; Unnikrishnan RI; Mohan V
Diabetes Technol Ther; 2010 Aug; 12(8):613-8. PubMed ID: 20615102
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.
Levin PA; Mersey JH; Zhou S; Bromberger LA
Endocr Pract; 2012; 18(1):17-25. PubMed ID: 21742605
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
[TBL] [Abstract][Full Text] [Related]
17. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
Diamant M; Van Gaal L; Guerci B; Stranks S; Han J; Malloy J; Boardman MK; Trautmann ME
Lancet Diabetes Endocrinol; 2014 Jun; 2(6):464-73. PubMed ID: 24731672
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
[TBL] [Abstract][Full Text] [Related]
19. [Sequential treatment with insulin glargine and metformin, and exenatide in a patient with newly diagnosed type-2 diabetes].
Kress S
Dtsch Med Wochenschr; 2010 May; 135(18):907-10. PubMed ID: 20425675
[TBL] [Abstract][Full Text] [Related]
20. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.
Nauck MA; Duran S; Kim D; Johns D; Northrup J; Festa A; Brodows R; Trautmann M
Diabetologia; 2007 Feb; 50(2):259-67. PubMed ID: 17160407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
